- The report contains detailed information about Complete Genomics, Inc. that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.
- Another part of the report is a SWOT-analysis carried out for Complete Genomics, Inc.. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company’s strengths, weaknesses, opportunities, and possible threats against it.
- The Complete Genomics, Inc. financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company’s long-term solvency. This sort of company's information will assist and strengthen your company’s decision-making processes.
- In the part that describes Complete Genomics, Inc. competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company’s competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company’s business and sales activities will be boosted by gaining an insight into your competitors’ businesses.
- Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of Complete Genomics, Inc. business.
About Complete Genomics, Inc.
Complete Genomics, Inc., a life sciences company, develops and commercializes a DNA sequencing platform for human genome sequencing and analysis.
Human Genome Sequencing Platform Technology
The companys genomics analysis platform combines its proprietary human sequencing technology with informatics and data management software to provide customers with data that is ready to be used for genome-based research.
The company's human genome sequencing service would be used in applications, such as cancer research; mendelian disease research; rare variant disease research; and clinical trial optimization. In addition to these research studies, its clinical applications would include companion diagnostics; cancer pathology; and universal diagnostics.
Proprietary Sequencing Technology
There are two primary components of its proprietary human genome sequencing technology: DNA nanoball (DNB) arrays and combinatorial probe-anchor ligation (cPAL) reads.
DNB Arrays: The company has developed an approach to preparing fragmented DNA for reading on its sequencing instruments. Using a biochemical process for copying DNA, the company reproduces each DNA fragment in a manner that connects all of the copies together in a head-to-tail configuration, forming a long single molecule of connected nucleotides. The company has developed proprietary techniques for causing each long single molecule to consolidate, or ball up, into a small particle of DNA that is called as DNB.
cPAL Read: To read the sequence of nucleotides in each DNB, the company has developed a proprietary ligase-based DNA reading technology called cPAL. The companys cPAL technology uses the naturally occurring ligase enzyme, which distinguishes between the A, C, T, and G nucleotides, to attach fluorescent molecules that light up with a different color for each of the four nucleotides.
High Throughput Process Automation
There are five major components of its high-throughput process automation technology: high-throughput sample preparation, high-throughput sequencing instruments, computing infrastructure, workflow automation software, and service delivery technology.
High-Throughput Sample Preparation: The companys sample preparation technology consists of step-by-step protocols for preparing DNA for sequencing and pipetting robots that automatically execute these protocols. The company prepares genomes samples in batches of 88 and loads the samples into a 96-well plate.
High-Throughput Sequencing Instruments: The companys sequencing instruments consist of a fluidics robot that pipettes multiple types of chemical reagents (including fluorescent molecules) onto the flow slides and an imaging system that records images of the fluorescent molecules attached to the DNA. Each sequencing instrument processes 18 flow slides at a time. Its sequencing instruments can generate between 50 and 70 gigabases of usable data from each flow slide in a 12-day run.
Computing Infrastructure: The company has built a genomic data processing facility that consists of approximately 5,000 core processors and 1,750 terabytes (a terabyte is one thousand gigabytes) of high-speed disk storage. The companys sequencing instruments are connected to its data center by a network connection that transfers data at a rate of 30 gigabits per second.
Workflow Automation Software: The companys workflow automation software tracks each sample from arrival at its facility to delivery of research-ready data to the customer. Sample tracking is accomplished through bar codes. Each 96-well plate of samples has a bar code, and each flow slide has a bar code.
Service Delivery Technology: The companys cloud-based data delivery system is based on its vendor relationship with Amazon Web Services (AWS). It uploads its customers finished genomic data to AWS, who copies the data to hard disks and ships the hard disks to its customers. The companys customers also can pay AWS to store their data on an ongoing basis.
Data Management Solution
There are two major components of its data management solution: assembly software and analysis software.
Assembly Software: The company has developed a proprietary approach to assembly that uses a combination of advanced data analysis algorithms and statistical modeling techniques to reconstruct the human genome from approximately two billion 70-base reads.
Analysis Software: The company is also developing a suite of additional analytical tools designed to enable its customers to analyze the data the company generates from their samples.
Customers and Markets
The company serves academic and government research centers, and biopharmaceutical companies. It operates in the United States, Canada, and Europe. Its customers include Academic Medical Center University of Amsterdam; Brigham & Womens Hospital; Broad Institute of MIT and Harvard; Childrens Hospital of Philadelphia; Eli Lilly and Company; Erasmus Medical Centre in Rotterdam, the Netherlands; Flanders Institute for Biotechnology; Genentech, Inc.; HudsonAlpha Institute for Biotechnology; Institute of Cancer Research United Kingdom; Institute of Molecular Medicine at the University of Texas Health Science Center at Houston; Institute for Systems Biology; National Cancer Institute; Ontario Institute for Cancer Research; Pfizer Inc.; and University of North Carolina.
The company's competitors include Illumina, Inc.; Life Technologies Corporation; and Roche Diagnostics Corporation.
Complete Genomics, Inc. was founded in 2005.
The above Company Fundamental Report is a half-ready report and contents are subject to change.
It means that we have all necessary data in our database to prepare the report but need 2-3 days to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.
1. COMPLETE GENOMICS, INC. COMPANY PROFILE
1.2. Financial Performance
1.3. Key Executives
1.4. Ownership and Major Holders
1.5. Company History
2. COMPLETE GENOMICS, INC. BUSINESS OVERVIEW
2.2. Major Products and Services
2.3. Markets and Sales Activities
2.4. Locations, Subsidiaries, Operating Units
3. COMPLETE GENOMICS, INC. SWOT ANALYSIS
4. COMPLETE GENOMICS, INC. FINANCIAL ANALYSIS
4.1.1. Income Statement
4.1.2. Balance Sheet
4.1.3. Cash Flow
4.2. Financial Ratios
4.2.2. Margin Analysis
4.2.3. Asset Turnover
4.2.4. Credit Ratios
4.2.5. Long-Term Solvency
4.2.6. Growth Over Prior Year
4.2.7. Financial Ratios Charts
4.3. Stock Market Snapshot
5. COMPLETE GENOMICS, INC. COMPETITORS AND INDUSTRY ANALYSIS
5.1. Complete Genomics, Inc. Direct Competitors
5.2. Comparison of Complete Genomics, Inc. and Direct Competitors Financial Ratios
5.3. Comparison of Complete Genomics, Inc. and Direct Competitors Stock Charts
5.4. Complete Genomics, Inc. Industry Analysis
5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
5.4.2. Complete Genomics, Inc. Industry Position Analysis
6. COMPLETE GENOMICS, INC. NEWS & EVENTS
6.1. News & PR Activity Analysis
6.2. IR Corporate News
6.3. Marketing News
6.4. Corporate Events
7. COMPLETE GENOMICS, INC. EXPERTS REVIEW1
7.1. Experts Opinion
7.2. Experts Estimates
8. COMPLETE GENOMICS, INC. ENHANCED SWOT ANALYSIS2
9. UNITED STATES PESTEL ANALYSIS2
9.2. Economic Factors
9.3. Social Factors
9.4. Technological Factors
9.5. Environmental Factors
9.6. Legal Factors
10. COMPLETE GENOMICS, INC. IFE, EFE, IE MATRICES2
10.2. External Factor Evaluation Matrix
10.3. Internal External Matrix
11. COMPLETE GENOMICS, INC. PORTER FIVE FORCES ANALYSIS2
12. COMPLETE GENOMICS, INC. VRIO ANALYSIS2
APPENDIX: RATIO DEFINITIONS
LIST OF TABLES
Complete Genomics, Inc. Key Facts
Income Statement Key Figures
Balance Sheet Key Figures
Cash Flow Statement Key Figures
Financial Performance Abbreviation Guide
Complete Genomics, Inc. Key Executives
Key Executives Biographies1
Key Executives Compensations1
Complete Genomics, Inc. Major Shareholders
Complete Genomics, Inc. History
Complete Genomics, Inc. Products
Revenues by Segment
Revenues by Region
Complete Genomics, Inc. Offices and Representations
Complete Genomics, Inc. SWOT Analysis
Yearly Income Statement Including Trends
Income Statement Latest 4 Quarters Including Trends
Yearly Balance Sheet Including Trends
Balance Sheet Latest 4 Quarters Including Trends
Yearly Cash Flow Including Trends
Cash Flow Latest 4 Quarters Including Trends
Complete Genomics, Inc. Profitability Ratios
Margin Analysis Ratios
Asset Turnover Ratios
Long-Term Solvency Ratios
Financial Ratios Growth Over Prior Year
Complete Genomics, Inc. Capital Market Snapshot
Complete Genomics, Inc. Direct Competitors Key Facts
Direct Competitors Profitability Ratios
Direct Competitors Margin Analysis Ratios
Direct Competitors Asset Turnover Ratios
Direct Competitors Credit Ratios
Direct Competitors Long-Term Solvency Ratios
Pharmaceuticals and Biotechnology Industry Statistics
Complete Genomics, Inc. Industry Position
Company vs. Industry Income Statement Analysis
Company vs. Industry Balance Sheet Analysis
Company vs. Industry Cash Flow Analysis
Company vs. Industry Ratios Comparison
Complete Genomics, Inc. Consensus Recommendations1
Analyst Recommendation Summary1
Price Target Summary1
Experts Recommendation Trends1
Revenue Estimates Analysis1
Earnings Estimates Analysis1
Revenue Estimates Trend1
Earnings Estimates Trend1
LIST OF FIGURES
Complete Genomics, Inc. Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit
Profit Margin Chart
Operating Margin Chart
Return on Equity (ROE) Chart
Return on Assets (ROA) Chart
Debt to Equity Chart
Current Ratio Chart
Complete Genomics, Inc. 1-year Stock Charts
Complete Genomics, Inc. 5-year Stock Charts
Complete Genomics, Inc. vs. Main Indexes 1-year Stock Chart
Complete Genomics, Inc. vs. Direct Competitors 1-year Stock Charts
Complete Genomics, Inc. Article Density Chart
2 – These sections are available only when you purchase a report with appropriate additional types of analyses.
The complete financial data is available for publicly traded companies.
Enhanced SWOT Analysis
- How to use the strengths to take advantage of the opportunities?
- How to use the strengths to reduce likelihood and impact of the threats?
- How to overcome the weaknesses that obstruct taking advantage of the opportunities?
- How to overcome the weaknesses that can make the threats a reality?
Key Factors Examined by PESTEL Analysis:
- Legal – What laws and legislation will exert influence on the style the business is carried out?
IFE, EFE, IE Matrices
Porter Five Forces Analysis
- What composes a threat of substitute products and services?
- Is there a threat of new competitors entering the market?
- What is the intensity of competitive rivalry?
- How big is the bargaining power of buyers?
- How significant is the bargaining power of suppliers?
- Tangible resources
- Intangible resources
- Innovation and Creativity
- Organizational capabilities
- Costly to imitate?
- Organized properly?